Riliprubart is named as an intervention in 3 current clinical trials in our USA, China and UK registers. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is Sanofi. The most-studied condition is Polyneuropathy, Inflammatory Demyelinating, Chronic.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141 · Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | Recruiting | Sanofi | UK, USA, China |
|
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099 · ClinicalTrials.gov ↗ · Polyneuropathy, Inflammatory Demyelinating, Chronic
|
Phase 3 | By invitation | Sanofi | UK, USA, China |
|
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
|
Phase 3 | Active, closed | Sanofi | USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Sanofi | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
| Clinical trials in China | 3 | 1 |
| Clinical trials in UK | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, China and UK registers name Riliprubart as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA, 1 with sites in China and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Sanofi. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Riliprubart works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Riliprubart works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Riliprubart (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.